1. Show article details.

    Hologic Launches its First Cart-Based Ultrasound System, SuperSonic™ MACH 40

    Business Wire – 8:08 AM ET 07/08/2020

    Latest innovation expands portfolio of ultrasound technologies with premium offering designed to enhance efficiency and accuracy Hologic, Inc. (HOLX) announced today the U.S. launch of the SuperSonic™ MACH 40 ultrasound system, expanding the Company’s suite of ultrasound technologies with its first premium, cart-based system. This press release features multimedia.

  2. Show article details.

    Hologic to Announce Financial Results for the Third Quarter of Fiscal 2020 on Wednesday, July 29, 2020

    Business Wire – 8:15 AM ET 07/02/2020

    Hologic, Inc. (HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2020 on Wednesday, July 29, after the market closes. Interested participants may listen to the call by dialing 800-263-0877 or +1 323-794-2094 and referencing access code 3113758.

  3. Show article details.

    BRIEF-Hologic Sees Q3 Diagnostics Revenue To Grow 20-25%

    Reuters – 4:41 PM ET 06/08/2020

    Hologic Inc (HOLX): * HOLOGIC INC SEES Q3 DIAGNOSTICS REVENUE TO GROW 20-25% * HOLOGIC INC SEES Q3 BREAST AND SKELETAL HEALTH REVENUE TO DECLINE 30-35%. * HOLOGIC INC SEES Q3 SURGICAL REVENUE TO DECLINE 65-70%. Source: https://bit.ly/2UoOhhp Further company coverage:

  4. Show article details.

    Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences

    Business Wire – 4:05 PM ET 06/01/2020

    Hologic, Inc. (HOLX) announced today that the Company will present at these upcoming virtual investor conferences: Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following the events.

  5. Show article details.

    Innovative Advancements in Medical Imaging Devices Hold the Potential to Save Lives

    PR Newswire – 9:00 AM ET 05/27/2020

    NEW YORK, May 27, 2020 The medical device industry is seeing strong growth thanks to new technologies and developing medical infrastructure around the world. Some of the fastest growing segments in the medical device market by application include diagnostic devices like patient-monitoring systems, MRI machines, diagnostic imaging equipment, and ultrasonic scanning devices.

  6. Show article details.

    Hologic's latest COVID-19 test gets FDA approval for emergency use

    Reuters – 9:08 AM ET 05/15/2020

    Hologic Inc (HOLX) said on Friday the U.S. Food and Drug Administration granted emergency use authorization for its COVID-19 diagnostic test that can provide initial results in about three hours and process more than 1,000 tests in 24 hours.

  7. Show article details.

    BRIEF-Hologic Granted FDA Emergency Use Authorization For Its Second Molecular Test For Covid-19

    Reuters – 8:37 AM ET 05/15/2020

    Hologic Inc (HOLX): * HOLOGIC GRANTED FDA EMERGENCY USE AUTHORIZATION FOR ITS SECOND MOLECULAR TEST FOR COVID-19. * Hologic Inc (HOLX) - HOLOGIC HAS BEGUN DISTRIBUTING ITS NEW CORONAVIRUS TEST, AND EXPECTS TO PRODUCE AN AVERAGE OF ONE MILLION TESTS PER WEEK.

  8. Show article details.

    Hologic Granted FDA Emergency Use Authorization for Its Second Molecular Test for COVID-19

    Business Wire – 8:01 AM ET 05/15/2020

    -- Significant Test Manufacturing Capacity, Large Installed Base of Automated Instruments Yield Testing Breakthrough -- Hologic, Inc. (HOLX) announced today that it has received Emergency Use Authorization from the U.S. Food and Drug Administration for its Aptima SARS-CoV-2 assay to detect the novel coronavirus. This press release features multimedia.

  9. Show article details.

    Hologic to Webcast Presentations at Upcoming Investor Conferences

    Business Wire – 8:15 AM ET 05/06/2020

    Hologic, Inc. (HOLX) announced today that the Company will present at these upcoming virtual investor conferences: Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following the events.

  10. Show article details.

    BRIEF-Hologic To Introduce Second High-Throughput Molecular Assay For Novel Coronavirus

    Reuters – 6:19 PM ET 04/29/2020

    * HOLOGIC TO INTRODUCE ITS SECOND HIGH-THROUGHPUT MOLECULAR ASSAY FOR THE NOVEL CORONAVIRUS. * HOLOGIC INC (HOLX) - PLANS TO LAUNCH A NEW APTIMA MOLECULAR ASSAY TO DETECT THE SARS-COV-2 VIRUS THAT WILL RUN ON ITS PANTHER SYSTEM. * HOLOGIC INC (HOLX) - STARTING IN LATE MAY, EXPECTS TO BEGIN PRODUCING AT LEAST 1 MILLION APTIMA SARS-COV-2 ASSAYS PER WEEK ON AVERAGE.

  11. Show article details.

    Hologic launches second COVID-19 test to help reach more Americans

    Reuters – 5:39 PM ET 04/29/2020

    Hologic Inc (HOLX) on Wednesday said it is launching a second COVID-19 test that will help to dramatically expand testing capabilities in the United States. The molecular assay to detect the SARS-CoV-2 virus will run on its Panther system. Beginning next week, the company will distribute three million tests to around 1,000 hospitals and public health labs nationwide.

  12. Show article details.

    BRIEF-Hologic Reports Financial Results For Q2 2020

    Reuters – 4:04 PM ET 04/29/2020

    Hologic Inc (HOLX): * HOLOGIC ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL 2020. * Q2 NON-GAAP EARNINGS PER SHARE $0.57. * Q2 GAAP EARNINGS PER SHARE $0.36. * Q2 REVENUE $756.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $745.9 MILLION. * Q2 EARNINGS PER SHARE ESTIMATE $0.57 -- REFINITIV IBES DATA.

  13. Show article details.

    Hologic to Introduce Its Second High-Throughput Molecular Assay for the Novel Coronavirus (SARS-CoV-2)

    Business Wire – 4:01 PM ET 04/29/2020

    -- Company to Produce at Least One Million Tests a Week to Run on More than 1,000 Panther Instruments Installed in All 50 States -- -- Significant Assay Manufacturing Capacity Plus Large Installed Base of Fully Automated Systems Expected to Dramatically Increase Coronavirus Testing Capabilities, Helping Labs Deliver Results When and Where Needed -- -- HHS to Provide $13 Million of Advanced Deve...

  14. Show article details.

    Hologic Announces Financial Results for Second Quarter of Fiscal 2020

    Business Wire – 4:01 PM ET 04/29/2020

    – Revenue of $756.1 Million Declines 7.6% due to Cynosure Divestiture, 7.1% in Constant Currency –. – Organic Revenue Increases 0.5%, 1.1% in Constant Currency –. – Company Posts GAAP Diluted EPS of $0.36, Non-GAAP Diluted EPS of $0.57 –. – Company to Introduce Second High-Throughput Coronavirus Test for Panther® Platform –. MARLBOROUGH, Mass.

  15. Show article details.

    New York governor: Trump will get the truth when they meet

    Reuters – 12:50 PM ET 04/21/2020

    New York Governor Andrew Cuomo said he planned to give U.S. President Donald Trump an unvarnished account of what his state needs to test residents for the novel coronavirus when they meet in Washington on Tuesday.

  16. Show article details.

    New York governor: Trump will get the truth when they meet

    Reuters – 11:38 AM ET 04/21/2020

    - New York Governor Andrew Cuomo said he planned to give U.S. President Donald Trump an unvarnished account of what his state needs to test residents for the novel coronavirus when they meet in Washington on Tuesday.

Page:

Today's and Upcoming Events

  • Jul
    29

    HOLX to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Apr
    29

    HOLX announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.